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FOREWORD
Bipartisan support for the Dementia Initiative – Making Dementia a National Health Priority has 
provided a welcome and increased focus at the national level on a number of issues, including 
research.
The important initiatives taken in respect of funding for dementia grants and the three Dementia 
Collaborative Research Centres are a sign of national recognition that dementia research is an 
important part of any strategy in addressing the dementia epidemic.
Important though the initiatives of the last few years have been, it remains the case that dementia 
research is the poor cousin in medical research – and research on dementia care an even poorer 
cousin. In commissioning this report Alzheimer’s Australia has set out to demonstrate that on any 
objective basis, dementia research is under-funded. The impact of the dementia epidemic, whether 
on public health costs, social costs of families and carers, or the disability burden of the individual, 
suggests that Australia needs to make a more substantial investment for the future.
Alzheimer’s Australia would like to thank the JO & JR Wicking Trust for providing the funding for 
this research and to thank the authors of this report, Lee-Fay Low, Lisa Gomes and Henry Brodaty, 
for putting together what we hope is a useful document for policy makers and those responsible 
for setting priorities in respect of the Australian medical research effort.
I would also like to thank the Members of the Alzheimer’s Australia Research Medical and Scientific 
Panel for their comments on the draft of the Report.
Marc Budge
President 
Alzheimer’s Australia 
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EXECUTIVE SUMMARY
The dementia epidemic is here and has significant impact on health care and social costs in the 
wider community. In 2007 there were an estimated 220,050 people with dementia; by 2030 this 
figure will have more than doubled to 465,460 and by 2050 the figure will reach 731,030 people.  
Dementia is the chronic disease that is projected to show the greatest increase in disease burden 
by 2023. 
The direct cost to the heath and care system of dementia is projected to rise to $8.2 billion by 
2022-23. 
Investment in dementia research, whether in cause, cure or care, is a key strategy for addressing 
the epidemic. Historically, medical research in Australia has produced returns of $5 for every $1 
spent. 
Economic modelling has shown that if the onset of dementia could be delayed by 5 years there 
would be significant savings to the health and care system.
Australian researchers have contributed significantly to the global effort in dementia research and 
are world leaders in research on the aetiology of dementia, epidemiology, carers, and dementia 
management.
Relative to current disease burden and current direct cost of care, dementia research in Australia 
is significantly under-funded. Annual expenditure on dementia research is currently $12.8 million 
(0.57% of the total direct cost of dementia). In comparison with other major diseases, this is about:
 • 50% of research funding for cancer, relative to current disease burden.
 • 30% of research funding for cardiovascular disease, relative to current direct cost  
  of care. 
 • 20% of research funding for cancer and diabetes, relative to current direct    
  cost of care. 
 • 5% of current research funding for cancer, relative to predicted direct cost of care in 2023.
Recommendations:
 • Annual Australian expenditure on dementia research should be increased three-fold  
  to $36 million.  This would bring it more into line with expenditure on cardiovascular  
  and cancer research in relation to direct costs.
 • Investment in dementia research should be maintained at about 1.5% of the direct   
  cost of dementia and increase corresponding to costs over time.
 • Dementia should be included as a National Health Priority Area by the National   
  Health and Medical Research Council (NHMRC).
 • Priority should be given to research relating to dementia service delivery and   
  prevention as well as to translating dementia research findings into practice. 
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INTRODUCTION
Dementia is the umbrella term for a heterogenous group of disorders characterised by loss of 
memory and impairment to thinking and problem-solving capabilities. Dementia causes progressive 
neurodegeneration leading eventually to death. Common types of dementia are Alzheimer’s 
disease (50-70% of all dementia cases), vascular dementia (10-20% of cases), Lewy body 
dementia (10-20% of cases), and frontotemporal dementia (2% of cases).  
Many cases have a mixture of pathologies. Subtle changes in cognition and function can occur up 
to ten years before symptoms are apparent [1, 2]. The median survival time after symptom onset is 
4.5 years [3]; this varies with age and dementia subtype.
Australia has an ageing population as a result of the almost complete elimination of deaths from 
childhood infectious diseases; reductions in mortality from chronic systemic diseases, such as 
cardiovascular disease, cancer, and respiratory disorders; and the post WWII baby boom (1946-
1965) [4]. Age is the greatest risk factor for dementia [5], hence there are increasing numbers 
of persons with dementia. In 2007 there were an estimated 220,050 people with dementia 
representing 1.06% of the total population [6]. By 2030 this figure will have more than doubled to 
465,460 representing 1.88% of the population and by 2050 the figure will reach 731,030 or 2.77% 
of the population [6].
In 2003 dementia was the 11th largest cause of disease burden in Australia; by 2023 it will be 
the 4th largest cause [7]. Access Economics estimated that in 2002 the total cost of dementia 
was AUD 6.6 billion [8]. Using different parameters the Australian Institute of Health and Welfare 
estimated that in 2003 dementia direct costs were AUD 1.4 billion and this is projected to increase 
to AUD 8.2 billion by 2022-23 [7]. Similarly, the number of persons with dementia will increase in 
the Asia Pacific region from 13.7 million people with dementia in 2005 to 23.7 million in 2020, of 
whom 9.5 million will come from China and 5.5 million from India [9]. The projected financial and 
societal costs of the dementia epidemic are very high [8, 10] and these may be underestimates 
as the baby boomer generation is will demand more medical and health services than previous 
generations [11]. 
The neuropathological changes characteristic of Alzheimer’s disease, beta-amyloid plaques and 
neurofibrillary tangles, were first described by Alois Alzheimer in 1906. Research in dementia was 
limited until the 1980s, but since then there have been many developments [12]. For instance, 
we have a better understanding of the molecular and cellular changes that occur in the various 
dementias, leading to the development of five drug treatments that slow the worsening of 
symptoms of Alzheimer’s disease[13]. Growth of new neurons and neuronal connections have 
been observed in adult human brains, suggesting that lost neurons may be replaced [14] A large 
number of modifiable risk factors for dementia have been identified, including low education, 
head injury, high blood pressure and physical and mental inactivity [15]. There have also been 
developments in neuropsychological testing and neuroimaging, leading to earlier diagnosis [16].
Understanding the negative consequences of behavioural and psychological symptoms of 
dementia has led to the development of pharmaceutical and non-pharmaceutical treatments [17]. 
Recognition of the important role of families in the care of persons with dementia, and the stressors 
that accompany this role, have led to improvements in support and services for carers [18, 19].
But fundamental questions remain [12]: 
 • There is no consensus on the causes of Alzheimer’s disease, Lewy body disease,  
 or frontotemporal dementia. 
 • The epidemiology of dementia at the extremes of age (i.e. in the young and in the   
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 very old); persons from culturally and linguistically diverse (CALD) backgrounds;   
 Australian Aboriginal and Torres Strait Islanders; and persons with developmental   
 delay, has not been fully described.
 • There is only consistent evidence for one susceptibility gene for non-familial forms of  
 dementia. It is likely that there are others.
 • There are no dementia treatments that reverse or halt any form of the disease.
 • There is no simple, accurate method for diagnosing very early dementia. 
 • It is not known which, when, and by how much, risk factors need to be modified in   
 order to delay or prevent dementia. 
 • The best models to meet the care needs of persons with dementia, including the   
 role of community care, have not been identified to maximise quality-of-life and cost-  
 effectiveness. 
 • People with dementia rarely have a voice. We need to advance our knowledge   
 of their experiences, perspectives, and ways of communicating at different stages of   
 the disease.
 • It is not clear how to best train nurses, doctors, allied health and other paid carers,   
 in supporting persons with dementia and minimising its impact on these care    
 professionals.
 • We know very little about how to translate the best evidence into practice.
Australia is a small country with limited resources and needs to conduct priority-driven research 
[20]. Investment in Australian medical research and development has historically produced 
excellent returns of up to $5 for every $1 invested [21]. This decade is crucial in responding to the 
dementia epidemic because  commencement of a research program and implementation of the 
outcomes in policy and practice. In 2005 dementia was made a National Health Priority by the 
Australian Government. Sixteen million dollars was allocated for dementia research project grants 
and $7 million was awarded over three years for three Dementia Collaborative Research Centres 
(DCRCs). The Dementia, A National Health Priority Initiative is being evaluated by the LAMA 
(LaTrobe University, Access Economics, Monash University and Aged Care Solutions) consortium. 
Continuity of funding is not guaranteed.
Is Australia investing enough in dementia research? What research areas should we be targeting? 
The National Framework for Action on Dementia 2006-2010 states that identification of key areas 
for national research is an immediate priority. The Federal-Government-commissioned Dementia 
Research Mapping project reviewed the international dementia literature and identified numerous 
gaps in all areas of dementia research [12], but the purview of the project did not include examining 
the state of Australian dementia research.
The aims of this report are:
1) To take stock of recent Australian dementia research to identify areas of strength    
and weakness; and,
2) To compare Australian dementia research funding levels with levels of research    
funding for other chronic diseases, and to levels of dementia research funding in the   
USA, UK, and Canada. 
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METHODOLOGY
Australian journal publications
Australian journal publications on dementia between 2005 and 2007 were obtained by searching 
Medline, PsychInfo, Cinahl, PubMed and Scopus databases on 3rd January 2008 for the keywords 
‘dementia’ or ‘Alzheimer’ or ‘mild cognitive impairment’. Australian journal publications were 
defined as having been conducted with an Australian sample (even if none of the authors were 
based in Australia at time of publication) or as having at least one author based at an Australian 
institute.
Book reviews, editorial introductions, errata, overviews of conference proceedings and abstracts 
were excluded from the publications reviewed.
Journal articles were classified according to Research Activity Codes developed by the UK Clinical 
Research Collaboration [22]. The Clinical Research Collaboration based the development of these 
codes on the Common Scientific Outlines of the International Cancer Research Partners, with 
input from industry and the Association of Medical Research Charities. They were refined after pilot 
studies. The Research Activity Codes categories are:
 a) Underpinning research
 b) Aetiology
 c) Prevention of disease and conditions, and promotion of well-being
 d) Detection, screening and diagnosis
 e) Development of treatments and therapeutic interventions
 f)  Evaluation of treatments and therapeutic interventions
 g) Management of disease and conditions
 h) Health and social care services research
We added the category ‘Carers’ to refer to research relating specifically to carers of persons with 
dementia. One author (LG) classified all the journal articles according to the descriptors provided 
for these codes. A second author (LFL) independently classified 30 randomly selected articles; the 
inter-rater reliability was 0.8. Journal articles presenting research on beta-amyloid, tau proteins, and 
risk factors were coded under b) Aetiology.
In addition, journal articles were classified according to dementia type (dementia in general, 
Alzheimer’s disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia, or 
other). Articles reporting on dementia in the special groups identified by the Dementia, A National 
Health Priority Initiative, were recorded. These special groups are: persons with younger onset 
dementia; persons from culturally and linguistically diverse (CALD) backgrounds; Aboriginal and 
Torres Strait Islanders; persons with developmental delay; and persons from rural and regional 
communities. The type of article (e.g. original research, review or other), and the types of research 
subjects (e.g. human participants, animals or cells), were also recorded.
The Elsevier Scopus database was searched on 14th May 2008 for all publications containing the 
keywords ‘dementia’ or ‘Alzheimer’ or ‘mild cognitive impairment. The number of Australian and all 
publications were tallied by year and the number of publications with 20 or more citations between 
2002-2007 were collated.
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Australian clinical trials
A search of the Australian Clinical Trials register, the Australian Consortium for Clinical Cognitive 
Research (AC4R) website, the US-hosted Clinical Trials Register, and Alzforum websites was 
undertaken for information on current Australian clinical trials relating to dementia. Information on 
the title of the trial, chief investigator, chief investigator’s research institution, sample size, type of 
dementia studied, and whether the trial was single or multi-site, were recorded for each clinical 
trial. Where it was unclear whether the trial was conducted in Australia, the chief investigator was 
contacted.   
Australian organisations conducting dementia research
A list of Australian organisations that had published dementia research between 2005 and 2007 or 
were conducting clinical trials (except for pharmaceutical companies), was drawn up. 
Historic research strengths
Information on Australian historic research strengths in dementia were collected by surveying the 
Alzheimer’s Australia Scientific and Medical Panel and its international contacts. 
Australian research funding
Data on Australian Government research funding for dementia and other chronic diseases (cancer, 
cardiovascular disease, diabetes, mental illness, and chronic respiratory disease) between 2002 
and 2007 were obtained from datasets on funded grants from the NHMRC and ARC websites. It 
is notable that the NHMRC includes grants that address several disease areas under more than 
one area of disease, such that the total of funding by disease area may exceed total NHMRC 
funding. State and territory government research funding data were gathered by searching state 
government and state health department websites for published reports and lists of funded 
research projects. The Medical Research Officer of the Health Department was contacted if the 
information was not publicly available.
A list of not-for-profit and for-profit organisations, which fund research into the disease areas 
of interest, was drawn up through a general internet search and search of the SPIN funding 
opportunities database. Data on the amount of research funding from each organisation on the 
list were then compiled from lists of research grants awarded, annual reports, and newsletters. 
Organisations were contacted for additional information.
The title and description (when available) of grants were used to categorise them by chronic 
disease.
The source of information and amount of funding for specific Australian organisations are listed in 
Appendix A (available online at www.alzheimers.org.au). 
Burden of disease and cost of care
Comparing research funding levels between chronic diseases is complex and inexact. To maximise 
comparability information for a data type was drawn from a single source whenever possible. 
Information on the current burden of disease for dementia and other chronic diseases was 
obtained from the most recent Australian burden of disease report [7]. The author of this report 
was contacted to obtain details about the projected burden of these diseases (Stephen Beggs, 
2007, personal communication).
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The current and projected direct costs of care for dementia and other chronic diseases were 
identified from the published literature. Information on the indirect cost of care was also collected 
from published literature, when available. Indirect costs of mental illness and chronic respiratory 
disease were estimated using the published ratio of indirect and direct costs. The amount of 
research funding relative to direct costs of care, and disease burden in disability adjusted life years 
(DALYs) was calculated for each chronic disease. 
 
International funding
A list of the major government departments responsible for funding medical research in the US, 
the UK, and Canada was compiled from published reports and through correspondence with 
Alzheimer’s organisations in those countries. The websites of these departments were then 
searched for data sets, published reports and other documents reporting government spending on 
dementia research.
The major Alzheimer’s organisation(s) in the US, the UK, and Canada, who provide dementia 
research funding, were identified. The Wellcome Trust was also identified as a major source of 
research funding in the UK and included in the funding data. The websites of these organisations 
were searched for current and past amounts of funding awarded for dementia research and 
organisations were contacted when necessary.
The sources of information and the amount of funding for international organisations are listed in 
Appendix B (available online at www.alzheimers.org.au).
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RESULTS
Australian dementia research
Australian dementia publications 
Australian researchers are well-represented and well-cited in dementia research.  
The Scopus database showed that up to the 14th May 2008 2.3% of all dementia publications had 
Australian authors. Between 2002 and 2007 14.2% of Australian dementia publications had been 
cited 20 or more times compared with 13.0% of the worldwide dementia literature. The number of 
Australian dementia publications is growing with the increasing global trend (see Figure 1).
  FIGURE 1  Dementia publications by year from Australia and the world 1964 - 2007
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  FIGURE 2  Journal publication classifications for dementia research 2005 - 2007
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Areas of Australian dementia research 2005-2007
We read the titles and abstracts (and full articles when necessary) of 551 Australian articles 
on dementia published between 2005 and 2007. The majority focused on dementia aetiology 
and underpinning research (see Figure 2). Fewer than 10% of articles addressed management, 
detection and diagnosis, and development of treatments. Fewer than 5% of articles were on 
evaluation of treatments, healthcare services, prevention, or carers.  
Half of the publications concentrated solely on Alzheimer’s disease, just over a third on dementia 
in general, and only small numbers on other types of dementia, such as vascular dementia, Lewy 
body dementia, and frontotemporal dementia (Figure 3).
  FIGURE 3  Type of dementia in journal articles 2005 - 2007
70
60
50
40
30
20
10
0
Alzheimer’s
%
  P
U
B
LI
S
H
E
D
Any Dementia Fronto-temporal Other dementia Lewy body Vascular
Sixty-three percent of publications reported original results (314 publications), 40% were reviews 
and 7% were book chapters, case-studies and opinion pieces. Just over 74%  
(240 studies) of studies reported on original research involving human participants,  
63 (19%) were cell studies and 22 (7%) were animal studies. Only a small number of journal 
publications related to special groups identified by the Dementia, A National Health Priority 
Initiative. Eight (1%) publications addressed younger onset dementia; seven (1%) were on 
dementia in rural and remote areas; four (<1%) were on persons with dementia from culturally and 
linguistically diverse (CALD) backgrounds; one publication was on persons with developmental 
delay and dementia; and one was on Aboriginal and Torres Strait Islander groups. 
Groups conducting dementia research 
Of 274 Australian organisations that had published dementia journal articles between 2005 and 
2007, 108 were university departments, 83 were research institutes, 55 were hospitals and 28 
were other health service providers. The majority of organisations were situated in New South 
Wales (34%) and Victoria (31%), with fewer organisations in Western Australia (12%), Queensland 
(9%), South Australia (7%), Tasmania (4%) and the Australian Capital Territory (3%). The full list 
of organisations and the number of publications from each are available in Appendix C (available 
online at www.alzheimers.org.au). 
Clinical trials 
The Australian and New Zealand Clinical Trials Register, the US-hosted clinical trials register and 
the Australasian Consortium of Centres for Clinical Cognitive Research (AC4R) website list16 
clinical trials on dementia currently being conducted in Australia. Eight are drug trials; five are 
Alzheimer’s Australia   15Australian Dementia Research: current status, future directions?
non-pharmaceutical trials (e.g. physical activity, behavioural support, music and aromatherapy); 
and three are focusing on the management of dementia. Nine of the trials have a multi-site design, 
most of which are drug trials and seven trials have only participants diagnosed with  
Alzheimer’s disease. The list of clinical trials is available in Appendix D (available online at  
www.alzheimers.org.au).  
Historic research strengths
A convenience sample of three members of the Alzheimer’s Australia’s Scientific and Medical Panel 
and five of their international contacts perceived the historical strengths of Australia’s dementia 
research to be in the areas of the aetiology of Alzheimer’s disease, epidemiology, carers and 
treatment and management. The following researchers are considered to be major contributors to 
Australian and international dementia research: 
Professor Colin Masters has been conducting research on the nature of dementia and other 
neurodegenerative disorders for more than 30 years. His seminal achievement has been in 
identifying the molecular and biochemical pathways underlying Alzheimer’s dementia, in particular 
the role of oxidative stress and beta-amyloid in the aetiology of the disease. This work is pivotal 
to future treatment developments. Professor Masters’ current research focuses on elucidating the 
roles of environmental and genetic factors in Alzheimer’s disease. 
Professor Tony Jorm has investigated the epidemiology of mental disorders, with articular focus 
on dementia and depression in the elderly, for more than 20 years. He co-led two major population 
studies, the Canberra Longitudinal Study for the Elderly and the Personality and Total Health (PATH) 
Through Life Project. Professor Jorm’s key papers on the prevalence, incidence, projections and 
risk factors for dementia helped to establish dementia as a national priority. 
Professor Henry Brodaty has researched clinical aspects of dementia, with a focus on diagnosis 
and management, for over 20 years. Professor Brodaty pioneered an intensive program for carers, 
which aimed at relieving stresses associated with caring for persons with dementia. Since this 
research, carers of persons with dementia have received greater recognition and support. His 
other projects have included a study of nursing home care for people with dementia, trials of 
anti-dementia drugs, and the development of a new dementia screening tool for use by general 
practitioners. 
Professor Ashley Bush has researched the aetiology and treatment of Alzheimer’s disease. Since 
1995, Professor Bush has been investigating the role of major proteins, in particular copper/zinc-
binding proteins, in the formation of senile plaques characteristic of Alzheimer’s disease. Based 
on these studies, Professor Bush has developed a new class of anti-Alzheimer’s drugs which are 
currently undergoing clinical trials.  
Professor David Ames is known for research on the treatment and management of Alzheimer’s 
disease including pharmacological treatments, and treatments for behavioural disturbance in 
dementia. He leads the Australian Imaging, Biomarker and Lifestyle (AIBL) Flagship Study of 
Ageing. Professor Ames has co-edited many books on dementia including Dementia, Guide to 
Psychiatry of Old Age and Cerebrovascular Disease, and Cognitive Impairment and Dementia and 
is currently editor of the journal International Psychogeriatrics. 
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Australian research funding for dementia compared with other 
chronic conditions 
Table 1 shows Australian government and non-government research funding between 2002 and 
2007 for dementia and other chronic diseases that account for a significant proportion of disease 
burden. The New South Wales state government awards block funding to large institutions ($177.7 
million in total 2002-07), therefore funding for specific diseases could not be determined. Thus 
NSW government funding is not included here. Cancer received the greatest total amount of 
funding, followed by cardiovascular disease (CVD), diabetes, mental illness and chronic respiratory 
disease (CRD). Government funding for cardiovascular disease was greatest, while cancer 
received the most non-government research funding. Dementia received the smallest amount of 
government and non-government research funding (see Figure 4). 
  TABLE 1  Total Australian research funding 2002-2007 for selected chronic diseases
 Chronic  ARC NHMRC  State Govt Total Govt  Non-govt  Total 
 Disease  Funding Funding Funding  Funding Funding Funding
  ($M) ($M) ($M) ($M) ($M) ($M)
 Dementia 20.0 52.5 0.1 72.7 3.9 76.6
 Cancer 65.7 497.9 17.1 580.7 179.1 759.8
 Cardiovascular  124.0 369.5 13.5 507.0 47.7 554.7
 Disease
 Diabetes 64.2 164.1 0.4 228.7 25.0 253.7
 Mental Illness 23.8 190.8 0.4 214.9 69.2 284.1
 Chronic  58.9 82.1 0.4 141.5 2.9 144.4
 Respiratory  
 Disease
  FIGURE 4  Research funding for dementia and other chronic diseases 2002 - 2007 
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The Australian Institute of Health and Welfare (AIHW) estimated Australian disease burden for 2003 
in terms of years of life lost (YLL), years lived with disability (YLD), and total burden measured in 
disability adjusted life years (DALY). These data are presented in Table 2.  
In 2003 cancer accounted for the greatest amount of total disability, as measured in lost DALYs, 
followed by cardiovascular disease, then mental disorders. Based on this data the AIHW projected 
the disease burden for 2023 and predicted that the greatest increases in burden will be attributable 
to dementia and diabetes, whereas the burden attributed to cardiovascular disease will fall. At 
average annual funding levels between 2002 and 2007 and 2003 DALY estimates, dementia 
received $135.24 per lost DALY per year for research funding, the equal second lowest amount 
per DALY compared to the other chronic diseases (see Figure 5). Research funding relative to 2003 
disease burden for dementia is approximately 50% that for cancer. At average annual funding 
levels (2002-2007) and 2023 DALY projections, dementia only received $66.14 per future lost 
DALY, the lowest amount per DALY (see Figure 6). 
 
  TABLE 2  Australian research funding and burden of disease for selected chronic      
 diseases in 2003 and 2023 [7] (Beggs, 2007, personal communication)
 Chronic  Average  2003  [7]  2023 % change 
 Disease  annual    projections 2003-2023
  funding
  2002-2007 YLL YLD DALY DALY  
  ($M)
 Dementia 12.8 24103 70296 94399 193031 104.5
 Cancer 126.6 411953 87463 499416 602384 20.6
 Cardiovascular  92.4 369365 104429 473794 433277 -8.6
 disease
 42.3 32295 111536 143831 288341 100.5
 Mental disorders 47.3 23154 327391 350545 393017 12.1
 Chronic  24.1 71339 115383 126157 227632 21.9
 Respiratory  
 Disease
  FIGURE 5  Research funding per DALY for 2003 
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  FIGURE 6  Research funding per DALY for 2023 
250
200
150
100
50
0
Dementia Cancer CVD Diabetes Mental 
Disorders
CRD
$ 
A
U
D
 
The most recent comparable Australian estimates of annual direct, indirect, and predicted costs 
of care for selected chronic diseases are shown in Table 3. Direct care costs include the cost of 
medical care, hospital care and medications. Indirect care costs include loss of productivity from 
both the person with the illness and his or her carers. These estimates show that mental illness 
has the greatest total cost of care, followed by cardiovascular disease and diabetes. Projections 
suggest that by 2023 dementia will have the highest direct care costs. Figures 7 and 8 show that 
dementia receives the lowest research funding per dollar of 2003 direct care costs (.57 cents) and 
per dollar of 2023 predicted direct care costs (.16 cents). Research funding per dollar of 2003 
direct care costs for dementia is approximately 30% of research funding per dollar of care costs for 
cardiovascular disease and less than 20% for cancer and diabetes.  Research funding per dollar of 
projected care costs for 2023 for dementia is approximately 5% of research funding per dollar of 
projected costs for cancer.
  TABLE 3 Australian cost of care for selected chronic diseases for 2000-01 and 2023
 Chronic  Direct cost Indirect Cost Total Cost Predicted %  
 Disease  of care of care of care Direct cost increase in 
  $M (AUD) $M (AUD) $M (AUD) of care cost of care
  2000-01 [7] 2000-01 2000-01 $M (AUD) 2000/01 -
     2022-23 2022-23
  
 Dementia 2230 2200 4430 8220 268.6
 Cancer 2918 6000 8918 4500 54.2
 Cardiovascular  5479 5700 11179 6840 24.8
 disease
 Diabetes 812 9261 10073 4210 418.5
 Mental disorders 3741 14964 18705 6690 78.8
 Chronic  3742 408 4150 730 -80.5
 Respiratory  
 Disease
Direct care cost data are from AIHW which are consistently about 1/3rd lower than figures 
estimated by Access Economics. Indirect cost data for dementia, cancer and cardiovascular 
disease are from [21], diabetes from [23] for 2005. Published ratios of direct and indirect costs 
were used to calculate indirect costs for mental illness [24] and chronic respiratory disease [25].
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  FIGURE 7  Research funding per $1 of 2000-01 direct cost of care
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  FIGURE 8  Research funding per $1 of 2023 direct care costs
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Australian dementia research funding compared to other 
select OECD countries.
Table 4 shows that total Australian government and Alzheimer’s organisation funding of dementia 
research is higher than counterpart organisations in the UK, similar to Canada and much lower 
than the USA. Australian funding for dementia research is much lower compared to the USA per 
capita (see figure 9) and in terms of the proportion of gross domestic product (GDP) spent on 
dementia research (see figure 10). 
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  TABLE 4  Dementia research funding in Australia, USA, UK and Canada in 2007
  Government  Alzheimer’s Government Total Government Total
  funding in Organisation  funding per funding per funding as funding as
  $M (AUD) funding in capita (AUD) capita (AUD) % of GDP % of GDP
   $M (AUD)
 
 Australia 15.3 0.2 0.73 0.74 0.0015 0.0015
 USA 724.7 21.4 2.39 2.46 0.051 0.052
 UK 19.2 6.1 +7.9 from  0.32 0.55 0.00015 0.00025
   Wellcome
   Trust
 Canada 26.0 2.4 0.79 0.86 0.002 0.0022
  FIGURE 9  Dementia research funding per capita in 2007
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  FIGURE 10  Dementia research funding relative to GDP in 2007
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DISCUSSION
Australia has, relative to its population (0.3% of the world population), contributed significantly to 
the global effort in dementia research (2.3% of dementia publications). Australian researchers are 
world leaders in understanding the aetiology of dementia, its epidemiology, carers, and dementia 
management.
Are we investing enough in dementia research?
Dementia research is significantly underfunded compared with the USA and relative to other 
chronic diseases in Australia. 
Australian dementia research funding would need to triple to be equivalent, per capita, to the USA. 
We only collected information on not-for-profit funding from the major Alzheimer’s organisations in 
the other countries and from the Wellcome Trust in the UK Not-for-profit funding in the US is five 
times, and in the UK three times, higher per capita than  in Australia [20]. Hence the total funding 
difference between Australia and the USA is likely to be even greater and the relatively low UK 
funding levels in comparison to the other countries considered here may be an underestimate. 
The research funding disparity between Australia and the USA is not specific to dementia. It 
was estimated that in 2000-01 Australia spent 1 to 2 cents per health dollar on research [21]. In 
comparison, in 2003 the USA spent 5.6 cents per health dollar on research [26]. 
Total dementia research funding would need to double to be equivalent to the amount per lost 
DALY spent on cancer research. Dementia research funding would need to increase more than 
fivefold to be equivalent to the proportion of current direct care costs spent on cancer or diabetes 
research. Since the estimated dementia care costs used here [7] are conservative compared with 
other estimates [8] the relative deficit may be larger.
Dementia is the chronic disease that is projected to show the greatest increase in disease burden 
by 2023. Current research funding does not reflect this projected increase. Funding would need 
to be increased seven-fold to equate to that received by diabetes, and increased eighteen-fold to 
equate to that given to cancer and chronic respiratory disease, relative to projected care costs. 
The proportion of non-government funding for dementia research is low compared to funding for 
cancer and mental illness. Philanthropic individuals and organisations need to be encouraged to 
support dementia research.
In 2005 dementia was made a National Health Priority by the Australian Government with $23 
million dollars awarded for research. This has attracted researchers to studying dementia. But the 
momentum that has been building will dissipate without continued funding. 
Are we researching the right areas?
Between 2005 and 2007 more than two thirds of dementia research publications reported on 
investigations into the causes and development of dementia and on understanding the functions 
and processes related to normal ageing.
There were limitations to this methodology: books and reports were not included, only book 
chapters listed on academic databases were included, information on contract research and 
unpublished research by private industry was not included and only three years of publications 
were examined. Research relating to health services may be therefore under-represented as it 
is often published in government or industry reports. Further, the majority of clients of aged care 
health services have dementia, but this label may not always be used in the title, keywords or 
abstract. 
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According to the NHMRC, cost per publication is lowest for biomedical research ($26,157), higher 
for clinical medicine ($32,398) and health services ($40,474), and greatest for public health and 
preventative medicine ($49,477). Taking into account these varying costs by research area and 
the limitations of our methodology, the data presented in this report suggest that research into 
the evaluation of treatments, management, health services and prevention has been relatively 
neglected. This may be because research in these areas usually requires longitudinal methodology 
with a large number of participants and therefore substantial funding. 
Research on the efficacy of pharmacological treatments and on some of the management 
strategies evaluated in other countries can be adopted relatively easily in Australia. But the 
Australian health system and Australian people and culture are unique. In order to determine 
how best to provide care and reduce disease risk, research into health services and prevention 
needs to be done in situ. The NHMRC has allocated a limited amount of funding specifically for 
health services research. There are also financial incentives to undertake health services research. 
Currently only 0.57% of the direct cost of dementia care is spent on research. Residential aged 
care comprises 85% of the direct cost of dementia, so services that delay institutionalisation could 
have considerable cost savings. It has been estimated that If the average onset of dementia had 
been delayed by five years from 2005 it would have resulted in a 50% reduction in new cases each 
year, and 35.2% fewer cases by 2020 and 48.5% fewer cases by 2040— a saving of $13.5 billion 
and by 2040 $67.5 billion [27]. 
Even the best research has little impact unless findings are known and incorporated into everyday 
practice. Much research is published in academic journals but does not reach practitioners or 
the public. Currently it takes an average of 17 years for research findings to be implemented in 
clinical practice [28]. Knowledge transfer is a long-term iterative process and requires specialist 
communicators, time, and money [29-31]. Researchers are usually not funded to translate and 
promulgate their results beyond publication and conference presentations. The NHMRC has 
recognised the need to improve access to good research evidence [32]. To get the most out of 
dementia research, funding needs to be allocated for the dissemination of results.
What needs to happen
 • Annual Australian expenditure on dementia research should be increased three-fold from  
  $12.8 million (0.57% of the total direct cost of dementia) to $36 million (1.6% of the total  
  direct cost)
 • Dementia should be made a National Health Priority Area by the National Health and  
  Medical Research Council.
 • Funding should be allocated specifically for dementia service delivery and prevention  
  research.
 • Funding should be allocated to disseminate dementia research findings.
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CONCLUSIONS 
The dementia epidemic is upon us. We need to prepare for the deluge through policy and service 
development, informed by research. Research funding for dementia must be at least trebled so 
that we can continue investigating areas of strength and address research gaps in service delivery 
and prevention. We must also ensure that results are translated into practice.
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